Genus (LON:GNS – Get Free Report) had its price objective increased by investment analysts at Berenberg Bank from GBX 3,050 to GBX 3,250 in a research note issued to investors on Friday, MarketBeat Ratings reports. The firm currently has a “buy” rating on the stock. Berenberg Bank’s price target suggests a potential upside of 14.64% from the company’s previous close.
Several other analysts have also issued reports on GNS. Deutsche Bank Aktiengesellschaft upped their price target on shares of Genus from GBX 2,900 to GBX 3,100 and gave the stock a “buy” rating in a research report on Wednesday, November 19th. Shore Capital upped their target price on shares of Genus from GBX 2,900 to GBX 3,000 and gave the company a “buy” rating in a report on Wednesday, November 19th. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Genus has a consensus rating of “Buy” and a consensus price target of GBX 3,116.67.
Check Out Our Latest Research Report on Genus
Genus Trading Up 7.8%
Genus Company Profile
Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands.
See Also
- Five stocks we like better than Genus
- Wall Street Alert: Buy AES
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- Do not delete, read immediately
- How a Family Trust May Be Able To Help Preserve Your Wealth
- NEW LAW: Congress Approves Setup For Digital Dollar?
Receive News & Ratings for Genus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genus and related companies with MarketBeat.com's FREE daily email newsletter.
